Avita Medical

What Avita Medical does

AVITA Medical is a publicly traded therapeutic acute wound care company (NASDAQ: RCEL; ASX: AVH) headquartered in Valencia, California, that develops and commercializes autologous cell-based regenerative medicine products for burn, trauma, surgical, and dermatologic wounds. Its core technology platform is the RECELL System, an FDA Premarket Approval–authorized device that enzymatically processes a small patient skin sample into a multi-phenotype cell suspension — containing keratinocytes, dermal fibroblasts, and melanocytes — applied at the point of care with a 1:80 donor-to-treatment expansion ratio. The next-generation RECELL GO (FDA-approved October 2024) automates this preparation with standardized incubation controls and is available in standard (1920 cm²) and mini (480 cm²) configurations. The company has extended its portfolio with PermeaDerm, an FDA-cleared biosynthetic dual-layer wound matrix, and Cohealyx, an FDA-cleared bovine collagen dermal matrix for full-thickness wound bed preparation, positioning AVITA as a multi-product wound-care platform rather than a single-device company.

AVITA generates revenue primarily through direct field sales of these single-use medical devices and matrices to a concentrated base of approximately 200 U.S. burn centers and Level 1 trauma centers, supported by a Scientific & Medical Affairs team and a reimbursement-support function (AVITA Patient Access Services). International revenue flows through distribution partners across CE-marked (Europe), TGA-certified (Australia), Medsafe-listed (New Zealand), and PMDA-approved (Japan) geographies, with RECELL GO receiving CE Mark in November 2025 and Australian TGA approval in April 2026. A 10-year Biomedical Advanced Research and Development Authority (BARDA) Project BioShield agreement signed in April 2026, valued at up to $25.5 million, adds a contracted government revenue stream for U.S. burn mass-casualty preparedness. FY2025 revenue was $71.6 million (11% year-over-year growth), Q1 2026 revenue was $19.3 million (4% year-over-year), and management has guided to $80–85 million for FY2026. Gross margins exceed 80%, though the company has not yet reached profitability (FY2025 EBITDA loss ~$40M) and is targeting free cash flow in 2026.

Name

Avita Medical

Legal name

AVITA Medical, Inc.

Website

https://avitamedical.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

251–500 employees

Short description

AVITA Medical is a publicly traded regenerative medicine company that develops and commercializes autologous cell-based wound care products — RECELL, PermeaDerm, and Cohealyx — sold primarily to U.S. burn centers and trauma hospitals, with expanding international distribution.

Ownership category

akta.pro rank

Product category

Therapeutic Acute Wound Care Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Wound & Ostomy Skin Care (Barrier Films/Creams, Adhesive Removers, Cleansers) (HLAHALAK)

Keywords

• Acute wound care
• Burn care devices
• Regenerative medicine
• Autologous cell therapy
• Dermal matrix products

Headquarters

HQ city

Valencia

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Product Sales: Sale of therapeutic wound care products including RECELL System, RECELL GO, PermeaDerm, and Cohealyx to hospitals, burn centers, and trauma centers. Products are single-use devices and matrices sold through direct field sales force in the US and through distribution partnerships internationally.
2. BARDA Government Contract: 10-year agreement with Biomedical Advanced Research and Development Authority (BARDA) worth up to $25.5M under Project BioShield. Provides BARDA access to 3,000 units of RECELL for U.S. burn emergency preparedness. Guaranteed revenue from annual maintenance fees plus procurement options.
3. Reimbursement Support Services: AVITA Patient Access Services (APAS) provides benefit verification, prior authorization, appeals, and case-specific support. Revenue flows indirectly through product utilization as reimbursement dynamics normalize.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels10 records

Core offering

AVITA Medical develops and commercializes therapeutic acute wound care products for hospitals, burn centers, and trauma centers. Its core offering is the RECELL System, an FDA-approved autologous cell harvesting device that processes a small sample of a patient's own skin into a Spray-On Skin Cells suspension applied at the point-of-care for thermal burn wounds and full-thickness skin defects. The portfolio also includes PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen dermal matrix for full-thickness wound management.

Product overview

AVITA Medical is a therapeutic acute wound care company with a portfolio of three FDA-cleared/approved products: RECELL (core platform technology - autologous cell harvesting device for burns and wounds), PermeaDerm (biosynthetic wound matrix for temporary wound coverage), and Cohealyx (collagen dermal matrix for wound bed preparation). RECELL uses the patient's own skin cells to create Spray-On Skin Cells applied at point-of-care. PermeaDerm provides dual-layer biosynthetic coverage for acute wounds. Cohealyx supports vascularization for graft readiness in full-thickness wounds. The portfolio addresses different aspects of wound care from cell-based therapy to wound bed preparation and coverage.

Differentiator

Problem solved

Functional benefit

Brands

• RECELL: FDA-approved autologous cell harvesting device that creates Spray-On Skin Cells for treatment of thermal burn wounds and full-thickness skin defects.
• RECELL GO
• PermeaDerm
• Cohealyx

Products and services

• RECELL System FDA-approved autologous cell harvesting device that processes a small piece of patient skin to create a Spray-On Skin Cells suspension for treatment of thermal burn wounds, full-thickness skin defects, and vitiligo at the point-of-care.
• RECELL GO Next-generation FDA-approved automated RECELL device that streamlines preparation of Spray-On Skin Cells with precise incubation time controls, designed for treating wounds up to 1920 cm2.
• RECELL GO mini Compact version of RECELL GO designed for treating smaller wounds up to 480 cm2.
• PermeaDerm FDA-cleared biosynthetic wound matrix with dual-layer design (outer silicone epidermal analogue and inner 3D micro-support system with porcine gelatin and aloe vera biocoating) for treatment of partial-thickness wounds, surgical wounds, trauma wounds, donor sites, and coverage of meshed autografts. Available in configurations including PermeaDerm C (161 cm2), PermeaDerm B (up to 2,903 cm2), and PermeaDerm Glove (406-1,023 cm2 for hand burns).
• Cohealyx FDA-cleared bovine dermal collagen matrix (Type I and III collagen) with uniform porosity designed for full-thickness wound management, supporting rapid cellular infiltration and vascularized tissue formation for earlier graft readiness.

Quantifiable outcome

• 97.5% reduction in donor skin requirements compared to 2:1 meshed autografting for deep partial-thickness burns
• +9 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Stoke Mandeville HospitalminorStrategic or Co-development Partner · 18 June 2026Clinical collaboration for first documented U.K. case series using RECELL GO. 17 burn and reconstructive surgery patients treated, reporting successful outcomes including uncomplicated donor-site healing, complete graft take, and workflow benefits. Supports RECELL GO expansion across Europe and U.K.
• MSAC (Medical Services Advisory Committee, Australia)coreOthers · 28 October 2025Australian government health technology assessment body endorsed RECELL as safe and effective, recommending its inclusion in Medicare Benefits Schedule for adults and children. Highlights RECELL's ability to improve outcomes, reduce hospital stays, and minimize scarring compared to traditional skin grafting. Enhances pathway for wider adoption in Australia.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Smith & Nephew: Global medical device company with an advanced wound management portfolio (skin substitutes, dressings, negative pressure wound therapy). AVITA's SVP US Commercial Sales previously spent 12 years at Smith & Nephew's advanced wound division, signaling direct overlap in the burn and wound care sales channel.
• Integra LifeSciences: Diversified medical device company with wound care, regenerative tissue technologies, and neurosurgery/orthopedics portfolios. Competes with AVITA across wound dressings, dermal matrices, and regenerative skin products, with broader scale and indication coverage.
• ConvaTec: Global medical products company with a leading advanced wound care franchise (Avelle, Aquacel, InnovaMatrix). Sells biosynthetic and biologic wound matrices into the same hospital channels as AVITA's PermeaDerm and Cohealyx.
• Coloplast: Global wound and skin care company with advanced wound care dressings, ostomy, and continence products. Competes broadly in the hospital and outpatient wound care channel where AVITA sells RECELL and its matrix products.
• Solventum (3M Health Care spin-off): Spun-off health care business (formerly 3M Health Care, including the Acelity/KCI acquisition) with a large advanced wound care and surgical portfolio. Overlaps with AVITA across wound dressings, negative pressure wound therapy, and skin substitute products in hospital burn and trauma centers.

Direct peers

• Organogenesis: Commercial-stage regenerative medicine company focused on skin and wound care, marketing Apligraf and other skin substitutes for chronic and acute wounds. Directly comparable to AVITA's RECELL and Cohealyx in targeting similar burn, surgical, and chronic wound indications with biologic/regenerative products.
• MiMedx: Wound care and regenerative medicine company selling placental tissue allografts (EpiFix, AmnioFix) for chronic wounds and surgical applications. Competes with AVITA in the advanced wound care and skin substitute market with overlapping hospital sales channels.
• Vericel: Cell therapy company marketing MACI (autologous cultured chondrocytes) and Epicel (cultured epidermal autografts) for severe burns. Epicel is a direct competitor to RECELL in autologous skin cell therapy for large burn injuries, making Vericel the closest cell-therapy analog.
• Stedical Scientific: Developer and owner of PermeaDerm, the biosynthetic wound matrix AVITA distributes in the US. Direct product-level partnership/peer relationship in the wound matrix category.

Emerging players

• PolarityTE: Regenerative medicine company developing autologous skin regeneration technology (SkinTE) for wounds and burns. Emerging, niche competitor in autologous skin cell/graft therapies overlapping with RECELL's regenerative wound care platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/avitamedical
• LinkedInlinkedin.com/company/avita-medical-limited
• Facebookfacebook.com/AvitaMedical

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds10 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avita Medical